BIOMARIN PHARMACEUTICAL INC
Public company snapshot, recent ticker-linked headlines, and a path into evidence-backed AI research.
Latest price
$58.51
+1.77%
Alpha Vantage · 10/30/2026
One-year price history
Adjusted daily closes · 252 observations · as of Oct 30, 2026
1 month
+0.1%
3 months
-2.5%
6 months
+8.2%
1 year
+12.7%
Year to date
-1.6%
52-week range
$49.67 – $70.24
Fundamental snapshot
Latest reported period: Jun 30, 2026
Market cap
$11.33B
P/E
155.2
P/B
1.8
P/S
3.3
Revenue
$3.41B
Net income
$72.97M
Diluted EPS
0.37
Gross margin
76.10%
Net margin
2.10%
Return on equity
1.20%
Total debt
$4.19B
Cash
$874.01M
Free cash flow
$738.18M
Latest eight reported quarters
Reported quarterly values, newest first
| Period | Revenue | Net income | Gross margin | Net margin | Free cash flow |
|---|---|---|---|---|---|
| Jun 30, 2026 | $989.71M | $44.76M | 79.50% | 4.50% | $139.29M |
| Mar 31, 2026 | $766.21M | $105.53M | 74.60% | 13.80% | $199.73M |
| Dec 31, 2025 | $874.57M | -$46.57M | 68.50% | -5.30% | $58.92M |
| Sep 30, 2025 | $776.13M | -$30.74M | 82.00% | -4.00% | $340.24M |
| Jun 30, 2025 | $825.41M | $240.53M | 81.80% | 29.10% | $168.17M |
| Mar 31, 2025 | $745.15M | $185.69M | 79.70% | 24.90% | $157.63M |
| Dec 31, 2024 | $747.31M | $124.94M | 81.80% | 16.70% | $166.1M |
| Sep 30, 2024 | $745.74M | $106.08M | 74.70% | 14.20% | $203.02M |
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Recent BMRN news
All market newsNo ticker-linked stories are in the current archive.